Clinical Trials Directory

Trials / Unknown

UnknownNCT02812654

Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment

The Use of Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Treatment of High-grade Extremity Soft Tissue and Non-metastatic Sarcomas

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
70 (estimated)
Sponsor
AC Camargo Cancer Center · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Prospective phase II study. Patients will be submitted to neoadjuvant chemotherapy (cT) and hypo fractionated radiotherapy (hRT) following by surgery. The remain viable cells will be analyzed and the patients whithin less than 30% will receive more 3 cycles of cT. All patients have deep high grade soft tissue sarcoma of extremity.

Detailed description

Prospective phase II non controlled study. Staging: All patients will be submitted to a local Magnetic Resonance (MR), Chest Tomography (CT) and Positron emission tomography-computed tomography (PET CT) previous to treatment. After the first cT cycle a new PET CT will be provided and one more at the end of the neoadjuvant treatment. Chemotherapy: cT neoadjuvant: Doxorubicin 75mg/m2 (cycles 1,2 and 3), and ifosfamide 9 g/m2 (cycles 1 and 3). Radiotherapy: RT 25 Gy / 5 x 500 cGy/day, beginning at Cycle 2/Day1. The surgery will be performed after 4-6 weeks from cycle 3. The remain of viable cells in surgical specimen will be analyzed and whether the the percentage value is less than 30% the patient will receive more 3 cycles of cT. A boost of RT is indicated if margins are considered R1 (microscopic positive margin).

Conditions

Interventions

TypeNameDescription
DRUGDoxorubicinDoxorubicin 75mg/m2 (cycle 1,2 and 3)
DRUGIfosfamideIfosfamide 9 g/m2 (cycle 1 and 3)
RADIATIONradiotherapyradiotherapy: 25 Gy / 5 x 500 cGy/day

Timeline

Start date
2015-03-01
Primary completion
2018-12-01
Completion
2019-03-01
First posted
2016-06-24
Last updated
2016-06-24

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT02812654. Inclusion in this directory is not an endorsement.